Triptolide exhibits antitumor effects by reversing hypermethylation of WIF-1 in lung cancer cells

Abstract

Triptolide (TP) exhibits numerous biological activities, including immunosuppressive, anti-inflammatory and antitumor effects. The aim of the present study was to investigate the role of TP as a potent therapeutic drug for the treatment of lung cancer and to investigate the underlying therapeutic mechanisms. Western blot analyses and reverse transcription-quantitative polymerase chain reaction (PCR) were performed to investigate the expression of genes at transcriptional and translational levels, respectively. Methylation-specific PCR assays were conducted to investigate whether TP affects the Wnt inhibitory factor-1 (WIF-1) methylation status and subsequently affects apoptosis, migration or the invasion of lung cancer cells. The results of the present study revealed that the methylation status of WIF-1 in lung cancer cell lines A549 and H460 was significantly enhanced compared with the human normal bronchial epithelial cell line HBE, whereas treatment with TP was revealed to induce the demethylation of WIF-1. The present study aimed to investigate whether the biological activities of TP are regulated by inhibiting the Wnt signaling pathway via an increase in WIF-1 expression levels. The results of the present study revealed that Wnt signaling was suppressed in cells following treatment with TP, which was concluded by the downregulation of Axin 2 and ß-catenin expression. Further investigation demonstrated that the silencing of WIF-1 expression with small interfering RNA reversed the TP-induced upregulation of WIF-1 expression, upregulated Axin 2 and ß-catenin expression and enhanced the activation of Wnt signaling. Notably, an upregulation of cellular tumor antigen p53 expression, and downregulation of matrix metalloproteinase-9 (MMP-9) and phosphorylated-nuclear factor-?B (NF-?B) P65 (p-P65) levels